The Establishment of Pan-Africa's First Biobank
Collecting data for better representation of genetic variability
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1538 results
EMA Starts Review of Meningioma Risk With Cyproterone Medicines
Recent study in France suggested that the risk of meningioma, although very low, may be increased when taking high doses of cyproterone for a long period
Recombinant Zoster Vaccine Reduces the Incidence of Herpes Zoster After Autologous HSCT
Results from a randomised trial in preventing herpes zoster in immunocompromised patients after autologous haematopoietic stem cell transplantation
FDA Grants Accelerated Approval to Selinexor for Multiple Myeloma
Approval is based on efficacy and safety results from Part 2 of the STORM study
Paraneoplastic Encephalitis in Testicular Cancer
KLHL11 identified as anovel paraneoplastic autoantibody
Night Shift Work Classified as Probably Carcinogenic to Humans
IARC update evaluation of carcinogenicity of night shift work
Molecular Characterisation of Non-functional Pancreatic Neuroendocrine Tumours
Robust molecular stratification provides insights into cell lineage correlates
EMA Recommends Extension of Indications for Ibrutinib
New indications concern combination with obinutuzumab for CLL and with rituximab for Waldenström’s macroglobulinaemia
FDA Approves Daratumumab for Multiple Myeloma Ineligible for Autologous Stem Cell Transplant
Approval is based on evidence from the MAIA study
Informed Consent Application for Azacitidine Celgene Received a Positive Opinion from the EMA
Marketing authorisation granted for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Daratumumab Shows Clinical Benefit in Combination With Standard of Care in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
CASSIOPEIA is the first phase III study to evaluate daratumumab in that setting
Population-level Impact of HPV Vaccination
Effectiveness of HPV vaccines in real-world settings based on up to 8 years of post-vaccination follow-up data